title: [A case report of conversion therapy for initially unresectable colorectal cancer liver metastases after cetuximab as third-line treatment].
abstract: The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer(mCRC)has significantly improved outcomes. There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy. For patients with isolated liver metastases, surgical resection is recommended when feasible. We experienced a case in which an initially unresectable mCRC liver metastases converted into a resectable one after cetuximab monotherapy as third-line treatment. The sample from hepatectomy was a pathologically complete response; no remnants were detected. The management of liver metastases contributes to improvements in the clinical setting. For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepaticsurgeons and diagnostic/therapeutic radiologists is indispensable. Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable CRC liver metastases in each hospital.
authors.affiliation: Dept. of Medical Oncology, Tochigi Cancer Center.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Tomomi
authors.initials: T
authors.lastname: Komaki
authors.forename: Junko
authors.initials: J
authors.lastname: Miyamoto
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Akutsu
authors.forename: Etsuko
authors.initials: E
authors.lastname: Warita
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamanaka
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kuroki
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Shirakawa
authors.forename: Heita
authors.initials: H
authors.lastname: Ozawa
authors.forename: Morihiro
authors.initials: M
authors.lastname: Tomikawa
authors.forename: Shoichi
authors.initials: S
authors.lastname: Hishinuma
authors.forename: Sayuri
authors.initials: S
authors.lastname: Hoshi
authors.forename: Seiji
authors.initials: S
authors.lastname: Igarashi
authors.forename: Tomoe
authors.initials: T
authors.lastname: Ozasa
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Sugano
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kotake
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab